ASX Announce PromarkerD US CMS price & TGA decision

Centers for Medicare & Medicaid Services (CMS) list PromarkerD predictive test for diabetic kidney disease and assign payment rate of US$390.75 in the United States.

CMS is the single largest payer for health care in the United States, with Medicare and Medicaid
collectively responsible for 42 per cent of healthcare spending and providing health coverage to
more than 100 million Americans.

The Australian Therapeutic Goods Administration (TGA) advises decision not to include the
PromarkerD test in the Australian Register of Therapeutic Goods (ARTG) due primarily to change
of manufacturer.

TGA decision does not affect Proteomics International’s activities in its primary markets of the
United States and Europe.

Approximately 32 million adults live with diabetes in the United States and 61 million in Europe,
as compared to 1.5 million in Australia.